Amicus Therapeutics (FOLD) discloses a preclinical Chaperone-Advanced Replacement Therapy...


Amicus Therapeutics (FOLD) discloses a preclinical Chaperone-Advanced Replacement Therapy program for the lysosomal storage disease Mucopolysaccharidosis Type I. The company says it has received a grant of $250K from a "private U.S.-based donor" in connection with its development of a treatment. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs